The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10168 malaria professionals are enjoying the free benefits of MalariaWorld today

Islamic Republic of Iran

Not Open Access | Lessons learnt from malaria epidemics in the Islamic Republic of Iran

October 16, 2012 - 17:17 -- Patrick Sampao
Author(s): 
Ostovar A, Raeisi A, Haghdoost AA, Ranjbar M, Rahimi A, Sheikhzadeh K, Majdzadeh R.
Reference: 
East Mediterr Health J. 2012 Aug;18(8):864-9.

MalariaWorldThis retrospective study presents the epidemiological characteristics and predisposing factors of 60 of the malaria epidemics reported in Sistan va Baluchestan province during 2005-09.

Medical Condition: 

Open Access | Survey for asymptomatic malaria cases in low transmission settings of Iran under elimination programme

May 2, 2012 - 08:23 -- Kabogo Ndegwa
Author(s): 
Zoghi S, Mehrizi AA, Raeisi A, Haghdoost AA, Turki H, Safari R, Ahmadi Kahanali A, Zakeri S
Reference: 
Malaria Journal 2012, 11:126 (25 April 2012)

MalariaWorldTaken together, the lack of asymptomatic carrier with the evidence of extremely low seropositive to both P. vivax and P. falciparum among examined individuals supported the limited recent transmission in the studied areas and, therefore, these parts of Iran have potential to eliminate the disease in the next few years.

Medical Condition: 

Molecular assessment of dhfr/dhps mutations among Plasmodium vivax clinical isolates after introduction of sulfadoxine/pyrimethamine in combination with artesunate in Iran

December 16, 2011 - 14:30 -- Patrick Sampao
Author(s): 
Mandana Afsharpad, Sedigheh Zakeri, Sakineh Pirahmadi, Navid D. Djadid
Reference: 
Infection, Genetics and Evolution, Volume 12, Issue 1, January 2012, Pages 38-44

MalariaWorldIn conclusion, the present results suggest that SP could be effective in treatment against the erythrocytic stages of vivax malaria in Iran; however, the increased frequency of mutant haplotypes in Iran since 2006 is worrying and indicates the emergence of drug-tolerant/resistant P. vivax isolates in Iran in near future.

Medical Condition: 
Medical Treatment: 

Molecular monitoring of Plasmodium falciparum resistance to antimalarial drugs after adoption of sulfadoxine–pyrimethamine plus artesunate as the first line treatment in Iran

November 17, 2011 - 11:09 -- Kabogo Ndegwa
Author(s): 
Mandana Afsharpad, Sedigheh Zakeri, Sakineh Pirahmadi, Navid Dinparast Djadid
Reference: 
Acta Tropica, Volume 121, Issue 1, January 2012, Pages 13-18

MalariaWorldThe main objective of this investigation was whether the combination therapy of sulfadoxine pyrimethamine (SP) plus artesunate (AS) protects against the spread of resistance to SP in malaria-endemic south-eastern Iran.

Medical Condition: 
Medical Treatment: 
Subscribe to RSS - Islamic Republic of Iran